These results demonstrate that mitochondrial translation inhibition via tigecycline creates a cellular state that significantly enhances sensitivity to HDAC inhibition in a dose-dependent manner across different RCC cell lines. This evidence concerns the gene HDAC9 and renal cell carcinoma.